EyePoint Pharmaceuticals Inc
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
EYPT$0.36+0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands except share data)
| December 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $99,704 | $281,263 |
| Marketable securities | 271,209 | 49,787 |
| Accounts and other receivables, net | 607 | 805 |
| Prepaid expenses and other current assets | 9,481 | 9,039 |
| Inventory | 2,305 | 3,906 |
| Total current assets | 383,306 | 344,800 |
| Property and equipment, net | 8,177 | 5,251 |
| Operating lease right-of-use assets | 21,000 | 4,983 |
| Restricted cash | 150 | 150 |
| Other assets | 5,832 | — |
| Total assets | $418,465 | $355,184 |
| Liabilities and stockholders' equity | ||
| Current liabilities: | ||
| Accounts payable | $11,721 | $6,504 |
| Accrued expenses | 18,103 | 17,521 |
| Deferred revenue | 17,784 | 38,592 |
| Other current liabilities | 1,440 | 646 |
| Total current liabilities | 49,048 | 63,263 |
| Deferred revenue – noncurrent | 10,853 | 20,692 |
| Operating lease liabilities – noncurrent | 21,858 | 4,906 |
| Other noncurrent liabilities | 205 | — |
| Total liabilities | 81,964 | 88,861 |
| Contingencies (Note 15) | ||
| Stockholders' equity: | ||
| Preferred stock, $.001 par value, 5,000,000 shares authorized, no shares issued and outstanding | — | — |
| Common stock, $.001 par value, 300,000,000 shares authorized at December 31, 2024 and December 31, 2023; 68,266,005 and 49,043,074 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively | 68 | 49 |
| Additional paid-in capital | 1,208,421 | 1,007,556 |
| Accumulated deficit | (873,016) | (742,146) |
| Accumulated other comprehensive income | 1,028 | 864 |
| Total stockholders' equity | 336,501 | 266,323 |
| Total liabilities and stockholders' equity | $418,465 | $355,184 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.